Deucravacitinib Clinical Trials (2026): 53 Studies for Psoriasis & Plaque Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
53 Deucravacitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 30 indications (including Psoriasis & Plaque Psoriasis) and 18,263 total planned enrollment. 12 Phase 3 Deucravacitinib trials and 11 Phase 2, 11 Phase 4 are listed. 19 Deucravacitinib clinical trials are actively recruiting at 115 U.S. sites across 27 states. Most recent activity: NCT06979453 (Aug 2034).
Where to Participate: All Deucravacitinib Trial Sites in the U.S. (115 sites across 27 states)
Every actively recruiting Deucravacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Alliance Dermatology | Phoenix85032 | NCT07116967 | Map |
| AZ | Medical Dermatology Specialists - Phoenix | Phoenix85006-2722 | NCT07116967 | Map |
| AZ | Omni Dermatology | Phoenix85018 | NCT07116967 | Map |
| AZ | Saguaro Dermatology - Phoenix | Phoenix85008 | NCT07116967 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT06444399 | Map |
| AZ | Scottsdale Clinical Trials | Scottsdale85260 | NCT07116967 | Map |
| AZ | Omni Dermatology | Tempe85282 | NCT07116967 | Map |
| AR | Clinical Trials Institute of Northwest Arkansas | Fayetteville72703-6245 | NCT07116967 | Map |
| AR | Northwest Arkansas Clinical Trials Center (NWACTC), PLLC | Rogers72758 | NCT07116967 | Map |
| CA | California Dermatology & Clinical Research Institute | Encinitas92024-7700 | NCT07116967 | Map |
| CA | T. Joseph Raoof MD Inc | Encino91436 | NCT07116967 | Map |
| CA | First OC Dermatology - Fountain Valley | Fountain Valley92708 | NCT07116967 | Map |
| CA | Center For Dermatology Clinical Research, Inc. | Fremont94538 | NCT06979453 | Map |
| CA | Center For Dermatology Clinical Research, Inc. | Fremont94538 | NCT07116967 | Map |
| CA | Marvel Clinical Research | Huntington Beach92647 | NCT07116967 | Map |
| CA | University of California San Diego | La Jolla92037 | NCT07017699 | Map |
| CA | Dermatology Research Associates | Los Angeles90045 | NCT06979453 | Map |
| CA | Dermatology Research Associates - Howard Sofen, MD | Los Angeles90045 | NCT07116967 | Map |
| CA | Northridge Clinical Trials | Northridge91325 | NCT06979453 | Map |
| CA | Northridge Clinical Trials - Elite Clinical Network | Northridge91325 | NCT07116967 | Map |
| CA | Cura Clinical Research - Palmdale | Palmdale93551 | NCT07116967 | Map |
| CA | Pasadena Clinical Trials | Pasadena91101 | NCT07116967 | Map |
| CA | Empire Clinical Research - Pomona | Pomona91767 | NCT07116967 | Map |
| CA | Integrative Skin Science and Research | Sacramento95815 | NCT07116967 | Map |
| CA | UC Davis Dermatology Clinic | Sacramento95816 | NCT07116967 | Map |
| CA | University of California, San Francisco | San Francisco94115 | NCT05858645 | Map |
| CA | Cura Clinical Research - Santa Clarita | Santa Clarita91355 | NCT07116967 | Map |
| CA | Clinical Science Institute | Santa Monica90404 | NCT07116967 | Map |
| CA | Advanced Dermatology and Skin Cancer Institute - Beverly Hills | Sherman Oaks91403 | NCT07116967 | Map |
| CA | Unison Clinical Trials | Sherman Oaks91403 | NCT07116967 | Map |
| CA | Golden State Dermatology - Walnut Creek - Ygnacio Valley Road | Walnut Creek94598 | NCT06979453 | Map |
| CA | Golden State Dermatology - Ygnacio Valley Road | Walnut Creek94598-3335 | NCT07116967 | Map |
| CO | Clarity Dermatology PLLC - Castle Rock | Castle Rock80109 | NCT07116967 | Map |
| CO | Paradigm Clinical Research, LLC | Wheat Ridge80033 | NCT06979453 | Map |
| FL | Skin Care Research LLC (SCR) - Boca Raton | Boca Raton33486 | NCT07116967 | Map |
| FL | Driven Research LLC | Coral Gables33134 | NCT07116967 | Map |
| FL | Florida Academic Dermatology Center | Coral Gables33134 | NCT07116967 | Map |
| FL | Accel Research Sites - Maitland Clinical Research Unit | Maitland32751 | NCT07116967 | Map |
| FL | Life Clinical Trials | Margate33063 | NCT06979453 | Map |
| FL | BioResearch Partner (BRP) - Miami | Miami33155 | NCT07116967 | Map |
| FL | International GCC Research | Miami33135 | NCT07116967 | Map |
| FL | Miami Dermatology and Laser Research | Miami33133 | NCT07116967 | Map |
| FL | Skin Research of South Florida | Miami33173 | NCT06979453 | Map |
| FL | Wellness Clinical Research | Miami Lakes33016 | NCT06979453 | Map |
| FL | Renstar Medical Research | Ocala34471 | NCT07116967 | Map |
| FL | LENUS Research | Sweetwater33172 | NCT07116967 | Map |
| FL | MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research | Tampa33607 | NCT06979453 | Map |
| FL | USF Health | Tampa33612 | NCT06979453 | Map |
| GA | Hamilton Dermatology (Atlanta Dermatology, Vein & Research Center, LLC) | Alpharetta30022 | NCT07116967 | Map |
| GA | Dermatology Affiliates Research Institute | Atlanta30305 | NCT06979453 | Map |
| GA | Advanced Medical Research, PC. | Sandy Springs30328 | NCT06979453 | Map |
| GA | Velocity Clinical Research, Savannah | Savannah31406 | NCT07116967 | Map |
| IL | Endeavor Health Clinical Trials | Skokie60077 | NCT07116967 | Map |
| IN | Deaconess Clinic Downtown | Evansville47708 | NCT07116967 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT06979453 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT07116967 | Map |
| IN | Southern Indiana Clinical trials | New Albany47150 | NCT07116967 | Map |
| KY | Equity Medical - Bowling Green | Bowling Green42104 | NCT07116967 | Map |
| KY | Physician Skin Care, PLLC | Louisville40217 | NCT07116967 | Map |
| LA | Clinical Trials Management, LLC - Northshore Office | Covington70433 | NCT07116967 | Map |
| LA | Shondra L. Smith, MD - Dermatology and Advanced Aesthetics | Lake Charles70605 | NCT07116967 | Map |
| LA | Clinical Trials Management | Metairie70006 | NCT07116967 | Map |
| MD | Dermatology and Skin Cancer Specialists, LLC | Rockville20850 | NCT06979453 | Map |
| MD | Lawrence J. Green, MD. LLC | Rockville20850 | NCT07116967 | Map |
| MD | U.S. Dermatology Partners Rockville | Rockville20850 | NCT07116967 | Map |
| MA | Metro Boston Clinical Partners | Brighton02135 | NCT07116967 | Map |
| MA | Kuchnir Dermatology & Dermatologic Surgery | Milford01757 | NCT06979453 | Map |
| MA | Kuchnir Dermatology & Dermatologic Surgery | Milford01757 | NCT07116967 | Map |
| MA | Local Institution | Waltham02451 | NCT05744466 | Map |
| MI | Oakland Hills Dermatology | Auburn Hills48326-3396 | NCT07116967 | Map |
| MI | Michigan Center for Skin Care Research | Clinton Township48038-1137 | NCT07116967 | Map |
| MI | Somerset Skin Centre | Troy48084-5260 | NCT07116967 | Map |
| MI | Michigan Dermatology Institute - Waterford | Waterford48328-3277 | NCT07116967 | Map |
| MN | Minnesota Clinical Study Center (MCSC) | New Brighton55112 | NCT07116967 | Map |
| MO | Saint Louis University | St Louis63110 | NCT07116967 | Map |
| NV | JDR Dermatology Research | Las Vegas89148 | NCT06979453 | Map |
| NV | Las Vegas Clinical Trials, LLC | North Las Vegas89030-7193 | NCT07116967 | Map |
| NH | StracSkin | Portsmouth03801 | NCT07116967 | Map |
| NY | Forest Hills Dermatology Group | Kew Gardens11415 | NCT07116967 | Map |
| NY | The Skin Center Dermatology Group | New City10956-7153 | NCT07116967 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT07508488 | Map |
| NY | Skin Search Rochester | Rochester14623-1507 | NCT07116967 | Map |
| NY | Elyse S. Rafal, MD PC - Rafal Center for Dermatology & Cosmetic Surgery | Stony Brook11790-2598 | NCT07116967 | Map |
| NY | Equity Medical - New York | The Bronx10455 | NCT07116967 | Map |
| NC | Accellacare - Cary | Cary27518 | NCT07116967 | Map |
| NC | Wilmington Dermatology Center-WDC Cosmetic and Research | Wilmington28405 | NCT07116967 | Map |
| OH | Apex Clinical Research Center - Canton | Canton44716 | NCT06979453 | Map |
| OH | Apex Clinical Research Center - Canton | Canton44718 | NCT07116967 | Map |
| OH | Wright State Physicians | Fairborn45324 | NCT07116967 | Map |
| OH | Dermatologists of Southwest Ohio | Mason45040 | NCT07116967 | Map |
| OH | Apex Clinical Research Center | Mayfield Heights44124 | NCT06979453 | Map |
| OH | Apex Clinical Research Center | Mayfield Heights44124 | NCT07116967 | Map |
| OH | Dermatology Partners Inc. - Medina Clinical Research | Medina44256-9312 | NCT07116967 | Map |
| OK | Central Sooner Research (CSR) - Oklahoma City | Oklahoma City73170 | NCT07116967 | Map |
| OK | Unity Clinical Research (UCR) | Oklahoma City73118-2864 | NCT07116967 | Map |
| OR | Velocity Clinical Research, Medford | Medford97504 | NCT07116967 | Map |
| OR | Oregon Dermatology and Research Center | Portland97210 | NCT07116967 | Map |
| OR | Oregon Medical Research Center | Portland97201 | NCT07116967 | Map |
| PA | Best Skin Research | Camp Hill17011-2308 | NCT07116967 | Map |
| PA | Paddington Testing Company | Philadelphia19103 | NCT06979453 | Map |
| PA | UPMC Department of Dermatology | Pittsburgh15213 | NCT07116967 | Map |
| SC | Palmetto Clinical Trial Services - Administrative Office | Anderson29621 | NCT07116967 | Map |
| SC | Palmetto Clinical Trial Services - Administrative Office | Greenville29615 | NCT07116967 | Map |
| TN | ObjectiveHealth - Goodlettsville Dermatology Research | Goodlettsville37072 | NCT06979453 | Map |
| TN | International Clinical Research (IC Research) - Murfreesboro | Murfreesboro37130 | NCT07116967 | Map |
| TX | Arlington Center for Dermatology | Arlington76011 | NCT07116967 | Map |
| TX | Studies in Dermatology, LLC | Cypress77429 | NCT07116967 | Map |
| TX | Modern Research Associates, PLLC | Dallas75231 | NCT07116967 | Map |
| TX | Center for Clinical Studies - Houston | Houston77065 | NCT07116967 | Map |
| TX | Texas Dermatology and Laser Specialists | San Antonio78218 | NCT06979453 | Map |
| TX | Texas Dermatology and Laser Specialists | San Antonio78218 | NCT07116967 | Map |
| TX | Center For Clinical Studies | Webster77598 | NCT07116967 | Map |
| WA | Frontier Derm Partners | Mill Creek98012 | NCT06979453 | Map |
| WA | Frontier Dermatology | Mill Creek98012 | NCT07116967 | Map |
| WA | Premier Clinical Research | Spokane99202 | NCT07116967 | Map |
Deucravacitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | 2 | |||||
| P1 | 3 | 3 | ||||||
| P2 | 3 | 2 | 2 | 2 | 2 | 11 | ||
| P2/P3 | 1 | 1 | ||||||
| P3 | 4 | 7 | 1 | 12 | ||||
| P4 | 1 | 5 | 2 | 3 | 11 | |||
| N/A | 7 | 4 | 1 | 1 | 13 |
Recruiting Deucravacitinib clinical trials (19)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06979453 | POETYK-PsO-PedA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | P3 | Plaque Psoriasis | 366 | Dec 2025 |
| NCT04772079 | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis | P3 | Plaque Psoriasis | 153 | Mar 2021 |
| NCT06869551 | BMS-986165A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis | P3 | Juvenile Psoriatic Arthritis | 60 | Mar 2025 |
| NCT07116967 | PRAGMATYKLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | P3 | Plaque Psoriasis | 3,040 | Sep 2025 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT06382987 | RePhlectA Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) | — | Plaque Psoriasis | 600 | Jan 2024 |
| NCT07017699 | A Study to Assess Deucravacitinib Safety in Pregnancy | — | Psoriasis (PsO) | 900 | Mar 2025 |
| NCT07508488 | Deucravacitinib in the Treatment of Cicatricial Alopecias | P2 | Central Centrifugal Cicatricial Alopecia | 20 | May 2026 |
| NCT06258668 | Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea | — | Moderate-to-severe Plaque Psoriasis | 505 | Aug 2024 |
| NCT05858645 | Correction of Psoriatic T Cell Signatures by Deucravacitinib | P4 | Psoriasis Vulgaris | 25 | Oct 2023 |
| NCT06701513 | A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect) | — | Psoriasis | 350 | Jan 2025 |
| NCT07013838 | The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis | P4 | Takayasu Arteritis (TAK) | 50 | Jun 2025 |
| NCT07280702 | COMBoDeucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease | P4 | Psoriatic Arthritis (PsA) | 128 | Apr 2026 |
| NCT05744466 | RePhlectA Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis | — | Psoriasis | 1,500 | Sep 2022 |
| NCT07256015 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | — | Psoriasis | 200 | Aug 2025 |
| NCT06136403 | GENEPIDA 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses | P2 | Epidermolysis Bullosa Simplex | 10 | Mar 2024 |
| NCT07564271 | Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies | — | Idiopathic Inflammatory Myopathies (IIMs) | 10 | Oct 2025 |
| NCT06999941 | A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features | — | Psoriasis | 50 | Apr 2025 |
| NCT06444399 | BMS-986165Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris | P2 | Pityriasis Rubra Pilaris | 12 | Jul 2024 |
Deucravacitinib clinical trials by indication
Psoriasis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06952465 | — | N/A | active not recruiting | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis |
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT06710470 | — | N/A | active not recruiting | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring |
| NCT06701513 | — | N/A | recruiting | A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect) |
| NCT05744466 | RePhlect | N/A | recruiting | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis |
| NCT07256015 | — | N/A | recruiting | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy |
| NCT06999941 | — | N/A | enrolling by invitation | A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features |
| NCT05701995 | ARTISTYK | P4 | completed | A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting |
| + 3 more, see All trials below. | ||||
Plaque Psoriasis (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06979453 | POETYK-PsO-Ped | P3 | recruiting | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis |
| NCT04772079 | — | P3 | recruiting | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis |
| NCT07116967 | PRAGMATYK | P3 | recruiting | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) |
| NCT06104644 | DELPHIN | N/A | active not recruiting | A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany |
| NCT06382987 | RePhlect | N/A | recruiting | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) |
| NCT06220604 | ICONIC-ADVANCE 2 | P3 | active not recruiting | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) |
| NCT06143878 | — | P3 | active not recruiting | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis |
| NCT06512337 | ADMIRE | N/A | active not recruiting | A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China |
| + 1 more, see All trials below. | ||||
Healthy Participants (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06566768 | BMS-986165 | P1 | completed | Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants |
| NCT06851871 | BMS-986165 | P1 | completed | A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults |
| NCT04949269 | — | P1 | completed | A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants |
Palmoplantar Pustulosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07000630 | — | N/A | terminated | Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis |
| NCT05710185 | — | P4 | terminated | Deucravacitinib for the Treatment of Palmoplantar Pustulosis |
Systemic Lupus Erythematosus (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05620407 | POETYK SLE-2 | P3 | active not recruiting | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus |
| NCT05617677 | POETYK SLE-1 | P3 | active not recruiting | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) |
Psoriatic Arthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04908202 | — | P3 | active not recruiting | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs |
| NCT04908189 | — | P3 | active not recruiting | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment |
Central Centrifugal Cicatricial Alopecia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07508488 | — | P2 | recruiting | Deucravacitinib in the Treatment of Cicatricial Alopecias |
Psoriatic Arthritis (PsA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07280702 | COMBo | P4 | not yet recruiting | Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease |
Idiopathic Inflammatory Myopathies (IIMs) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07564271 | — | N/A | recruiting | Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies |
Takayasu Arteritis (TAK) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07013838 | — | P4 | not yet recruiting | The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis |
Sarcoidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06725264 | TYK2 | P2 | withdrawn | Tyrosine Kinase 2 (TYK2) for GA and CS |
Psoriasis (PsO) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07017699 | — | N/A | recruiting | A Study to Assess Deucravacitinib Safety in Pregnancy |
Juvenile Psoriatic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06869551 | BMS-986165 | P3 | recruiting | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis |
Papulopustular Rosacea (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06532136 | — | P2 | withdrawn | Deucravacitinib Rosacea |
Moderate-to-severe Plaque Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06258668 | — | N/A | recruiting | Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea |
Pityriasis Rubra Pilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06444399 | BMS-986165 | P2 | recruiting | Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06476834 | — | P4 | completed | A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants |
Moderate Plaque Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06333860 | IMMpactful | P4 | completed | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
Vitiligo, Generalized (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06327321 | ViTYK | P2 | active not recruiting | Vitiligo Treatment by Targeting TYK2 Mediated Responses |
Pyoderma Gangrenosum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05821374 | — | Early P1 | withdrawn | Deucravacitinib in PG |
Epidermolysis Bullosa Simplex (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06136403 | GENEPID | P2 | recruiting | A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses |
Nail Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05124080 | — | Early P1 | completed | An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis |
Hidradenitis Suppurativa (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05997277 | HS | P2 | terminated | Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). |
Lichen Planopilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06091956 | — | P2 | completed | A Study of Deucravacitinib to Treat LPP and FFA |
Palmoplantar Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06042920 | — | P4 | terminated | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis |
Psoriasis Vulgaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05858645 | — | P4 | recruiting | Correction of Psoriatic T Cell Signatures by Deucravacitinib |
Sjögren's Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05946941 | POETYK SjS-1 | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome |
Alopecia Areata (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05556265 | — | P2 | terminated | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata |
Lupus Erythematosus, Discoid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04857034 | — | P2 | active not recruiting | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) |
Crohn Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04877990 | — | P2 | completed | A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis |
Deucravacitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| COMBo | NCT07280702 | P4 | not yet recruiting | Psoriatic Arthritis (PsA) | 128 | — |
| IMMpactful | NCT06333860 | P4 | completed | Moderate Plaque Psoriasis | 393 | — |
| ARTISTYK | NCT05701995 | P4 | completed | Psoriasis | 180 | — |
| POETYK-PsO-Ped | NCT06979453 | P3 | recruiting | Plaque Psoriasis | 366 | — |
| BMS-986165 | NCT06869551 | P3 | recruiting | Juvenile Psoriatic Arthritis | 60 | — |
| PRAGMATYK | NCT07116967 | P3 | recruiting | Plaque Psoriasis | 3,040 | — |
| POETYK SjS-1 | NCT05946941 | P3 | active not recruiting | Sjögren's Syndrome | 774 | — |
| POETYK SLE-2 | NCT05620407 | P3 | active not recruiting | Systemic Lupus Erythematosus | 513 | — |
| POETYK SLE-1 | NCT05617677 | P3 | active not recruiting | Systemic Lupus Erythematosus | 516 | PMID 40920289 |
| ICONIC-ADVANCE 2 | NCT06220604 | P3 | active not recruiting | Plaque Psoriasis | 731 | PMID 40976249 |
| TAK-279 | NCT06973291 | P3 | completed | Plaque Psoriasis | 606 | — |
| ViTYK | NCT06327321 | P2 | active not recruiting | Vitiligo, Generalized | 128 | — |
| GENEPID | NCT06136403 | P2 | recruiting | Epidermolysis Bullosa Simplex | 10 | — |
| BMS-986165 | NCT06444399 | P2 | recruiting | Pityriasis Rubra Pilaris | 12 | — |
| TYK2 | NCT06725264 | P2 | withdrawn | Sarcoidosis | 0 | — |
| HS | NCT05997277 | P2 | terminated | Hidradenitis Suppurativa | 7 | — |
Terminated and withdrawn Deucravacitinib trials (9)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06725264withdrawnTyrosine Kinase 2 (TYK2) for GA and CS
- NCT06532136withdrawnDeucravacitinib Rosacea
- NCT07000630terminatedEfficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
- NCT06042920terminatedA Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
- NCT05997277terminatedEvaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
- NCT06281106terminatedTYK2 Inhibition in Paradoxical Psoriasis
- NCT05710185terminatedDeucravacitinib for the Treatment of Palmoplantar Pustulosis
- NCT05556265terminatedA Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
- NCT05821374withdrawnDeucravacitinib in PG
All Deucravacitinib trials (53)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06979453 | POETYK-PsO-Ped | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis | P3 | recruiting | 366 | Bristol-Myers Squibb | Dec 2025 |
| NCT04772079 | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis | P3 | recruiting | 153 | Bristol-Myers Squibb | Mar 2021 | |
| NCT06952465 | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis | — | active not recruiting | 2,000 | Bristol-Myers Squibb | Jan 2025 | |
| NCT06869551 | BMS-986165 | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis | P3 | recruiting | 60 | Bristol-Myers Squibb | Mar 2025 |
| NCT07116967 | PRAGMATYK | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | P3 | recruiting | 3,040 | Bristol-Myers Squibb | Sep 2025 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT06104644 | DELPHIN | A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany | — | active not recruiting | 550 | Bristol-Myers Squibb | Apr 2023 |
| NCT06382987 | RePhlect | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) | — | recruiting | 600 | Bristol-Myers Squibb | Jan 2024 |
| NCT07017699 | A Study to Assess Deucravacitinib Safety in Pregnancy | — | recruiting | 900 | Bristol-Myers Squibb | Mar 2025 | |
| NCT06710470 | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | — | active not recruiting | 833 | Bristol-Myers Squibb | Aug 2024 | |
| NCT05946941 | POETYK SjS-1 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | P3 | active not recruiting | 774 | Bristol-Myers Squibb | Sep 2023 |
| NCT05620407 | POETYK SLE-2 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | P3 | active not recruiting | 513 | Bristol-Myers Squibb | Jan 2023 |
| NCT05617677 | POETYK SLE-1 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | P3 | active not recruiting | 516 | Bristol-Myers Squibb | Jan 2023 |
| NCT07508488 | Deucravacitinib in the Treatment of Cicatricial Alopecias | P2 | recruiting | 20 | Icahn School of Medicine at Mount Sinai | May 2026 | |
| NCT06258668 | Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea | — | recruiting | 505 | Bristol-Myers Squibb | Aug 2024 | |
| NCT05858645 | Correction of Psoriatic T Cell Signatures by Deucravacitinib | P4 | recruiting | 25 | University of California, San Francisco | Oct 2023 | |
| NCT06701513 | A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect) | — | recruiting | 350 | Bristol-Myers Squibb | Jan 2025 | |
| NCT07013838 | The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis | P4 | not yet recruiting | 50 | Chinese SLE Treatment And Research Group | Jun 2025 | |
| NCT04857034 | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | P2 | active not recruiting | 74 | Bristol-Myers Squibb | Jul 2021 | |
| NCT07280702 | COMBo | Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease | P4 | not yet recruiting | 128 | University of Texas Southwestern Medical Center | Apr 2026 |
| NCT05744466 | RePhlect | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis | — | recruiting | 1,500 | Bristol-Myers Squibb | Sep 2022 |
| NCT06220604 | ICONIC-ADVANCE 2 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | P3 | active not recruiting | 731 | Janssen Research & Development, LLC | Mar 2024 |
| NCT07256015 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | — | recruiting | 200 | Bristol-Myers Squibb | Aug 2025 | |
| NCT06327321 | ViTYK | Vitiligo Treatment by Targeting TYK2 Mediated Responses | P2 | active not recruiting | 128 | Centre Hospitalier Universitaire de Nice | May 2024 |
| NCT04908202 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | P3 | active not recruiting | 670 | Bristol-Myers Squibb | Jul 2021 | |
| NCT06143878 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | P3 | active not recruiting | 774 | Janssen Research & Development, LLC | Feb 2024 | |
| NCT06512337 | ADMIRE | A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | — | active not recruiting | 153 | Bristol-Myers Squibb | Jan 2025 |
| NCT04908189 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | P3 | active not recruiting | 729 | Bristol-Myers Squibb | Jul 2021 | |
| NCT06136403 | GENEPID | A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses | P2 | recruiting | 10 | Centre Hospitalier Universitaire de Nice | Mar 2024 |
| NCT07564271 | Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies | — | recruiting | 10 | Peking University People's Hospital | Oct 2025 | |
| NCT06999941 | A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features | — | enrolling by invitation | 50 | Xi Tan | Apr 2025 | |
| NCT06444399 | BMS-986165 | Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris | P2 | recruiting | 12 | Mayo Clinic | Jul 2024 |
| NCT06725264 | TYK2 | Tyrosine Kinase 2 (TYK2) for GA and CS | P2 | withdrawn | 0 | Yale University | Mar 2025 |
| NCT06973291 | TAK-279 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | P3 | completed | 606 | Takeda | Jul 2025 |
| NCT06333860 | IMMpactful | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | P4 | completed | 393 | AbbVie | May 2024 |
| NCT06532136 | Deucravacitinib Rosacea | P2 | withdrawn | 0 | Icahn School of Medicine at Mount Sinai | Nov 2024 | |
| NCT07000630 | Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis | N/A | terminated | 3 | Peking University First Hospital | Jun 2025 | |
| NCT05124080 | An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis | Early P1 | completed | 1 | University of Alabama at Birmingham | Mar 2024 | |
| NCT06566768 | BMS-986165 | Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants | P1 | completed | 52 | Bristol-Myers Squibb | Oct 2024 |
| NCT05701995 | ARTISTYK | A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | P4 | completed | 180 | Bristol-Myers Squibb | Jan 2023 |
| NCT06042920 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | P4 | terminated | 130 | Bristol-Myers Squibb | Oct 2023 | |
| NCT05997277 | HS | Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). | P2 | terminated | 7 | Beth Israel Deaconess Medical Center | Nov 2023 |
| NCT06851871 | BMS-986165 | A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults | P1 | completed | 26 | Bristol-Myers Squibb | Jan 2025 |
| NCT06281106 | TYPP | TYK2 Inhibition in Paradoxical Psoriasis | P2/P3 | terminated | 2 | Prof Curdin Conrad | Jun 2024 |
| NCT05710185 | Deucravacitinib for the Treatment of Palmoplantar Pustulosis | P4 | terminated | 3 | Brigham and Women's Hospital | Jul 2023 | |
| NCT06091956 | A Study of Deucravacitinib to Treat LPP and FFA | P2 | completed | 12 | Mayo Clinic | Nov 2023 | |
| NCT06476834 | A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants | P4 | completed | 8 | Bristol-Myers Squibb | Jun 2024 | |
| NCT05478499 | Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis | P4 | completed | 154 | Bristol-Myers Squibb | Oct 2022 | |
| NCT05556265 | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata | P2 | terminated | 94 | Bristol-Myers Squibb | Nov 2022 | |
| NCT05821374 | Deucravacitinib in PG | Early P1 | withdrawn | 0 | Dartmouth-Hitchcock Medical Center | Apr 2024 | |
| NCT06329258 | Combination of Sotyktu and Enstilar for Plaque Psoriasis | P4 | completed | 30 | Psoriasis Treatment Center of Central New Jersey | Dec 2022 | |
| NCT04877990 | A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis | P2 | completed | 67 | Bristol-Myers Squibb | May 2021 | |
| NCT04949269 | A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants | P1 | completed | 61 | Bristol-Myers Squibb | Jul 2021 |
Deucravacitinib clinical trials: frequently asked questions
- How many Deucravacitinib clinical trials are there?
- 53 Deucravacitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 16 are actively recruiting participants. 12 are marked completed.
- Are Deucravacitinib clinical trials recruiting in 2026?
- Yes — 16 Deucravacitinib trials are actively recruiting in 2026, with 115 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Deucravacitinib being studied for?
- Deucravacitinib is being studied for Psoriasis, Plaque Psoriasis, Healthy Participants, Palmoplantar Pustulosis, Systemic Lupus Erythematosus and 36 more. The trials are grouped by indication on this page.
- What phase is Deucravacitinib in?
- Deucravacitinib clinical trials span 11 Phase 4, 12 Phase 3, 11 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Deucravacitinib clinical trials?
- The lead sponsor across the most Deucravacitinib trials is Bristol-Myers Squibb, with 19 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Deucravacitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: